Humane Genomics vs Ankr
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synthetic oncolytic virus biotech engineering programmable cancer-killing RNA viruses; $8.12M raised with Union Square Ventures leading 2025 round competing in cancer immunotherapy.
About
Humane Genomics is a synthetic virology biotech company engineering oncolytic viruses — synthetic RNA viruses designed to selectively infect and destroy cancer cells while leaving healthy cells unharmed — using a proprietary platform that programs viral behavior at the genomic level to create next-generation cancer therapies. The company raised $8.12 million in total funding including a February 2025 round led by Union Square Ventures with 14 investor participants, developing RNA-based viral cancer therapies for systemic delivery designed for extended therapeutic activity.
Decentralized Web3 infrastructure with RPC node access across 30+ blockchains; globally distributed nodes reduce latency; premium dedicated nodes for apps needing guaranteed throughput.
About
Ankr is a Web3 infrastructure platform offering remote procedure call node access to more than 30 blockchain networks through a globally distributed network of nodes run by independent operators. Unlike centralized providers that operate their own data centers exclusively, Ankr's decentralized architecture routes requests across geographically distributed nodes, improving latency for users in regions underserved by US- or EU-centric infrastructure. Its public free-tier RPC endpoints — available for Ethereum, BNB Chain, Polygon, Avalanche, Fantom, and dozens of others — have made Ankr one of the most widely used infrastructure providers in the multi-chain developer ecosystem.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.